As per DelveInsight’s assessment, globally, Chronic Lower Back Pain pipeline constitutes 10+ key companies continuously ...

On June 3, 2025, the FDA granted Fast Track designation to CHM-CDH17, a third-generation CAR-T therapy targeting CDH17 for ...

Swedish biotech Camurus, known for developing long-acting treatments for chronic conditions, is reportedly in talks to buy US ...

Swedish biotech Camurus is reportedly in talks to acquire its US partner Braeburn Pharma in a deal that would give it full ...

Camurus AB reported its second-quarter earnings for 2025, revealing a robust financial performance with earnings per share (EPS) of 4.08, significantly surpassing the forecasted 3.27. The company’s ...

"Successful second quarter for Camurus" Summary second quarter 2025 April - June Total revenues grew 52% (65% at CER 1) to SEK 676 (445) million Sales of Buvidal ® increased 17% (26% at CER 1) to SEK ...

Camurus, an international, science-led biopharmaceutical company, announced that the European Commission (EC) has granted Oczyesa, octreotide subcutaneous depot, marketing authorization for the ...

First subcutaneous, once-monthly octreotide for treatment of acromegaly For convenient self-administration with a pre-filled autoinjector pen LUND, Sweden, July 1, 2025 /PRNewswire/ -- Camurus (NASDAQ ...

PLD is a rare genetic disorder causing progressive liver cysts, leading to severe symptoms and reduced quality of life. Approximately 37,000 people in the US and EU have PLD, most of whom are women.1 ...

CAM2029 reduces liver and cyst volume growth compared to placebo Well tolerated with no new or unexpected safety findings A follow-up Phase 3 study will be discussed with regulatory authorities PLD is ...